"World's Most Complete Market Research Reports Repository"

Global Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2025

This report studies the global market size of Postmenopausal Vaginal Atrophy Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Postmenopausal Vaginal Atrophy Drugs in these regions.
This research report categorizes the global Postmenopausal Vaginal Atrophy Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
In 2017, the global Postmenopausal Vaginal Atrophy Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Postmenopausal Vaginal Atrophy Drugs market based on company, product type, application and key regions.

The various contributors involved in the value chain of Postmenopausal Vaginal Atrophy Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Postmenopausal Vaginal Atrophy Drugs include
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.

Market Size Split by Type
by Estrogen-Based Drugs
Premarin
Vagifem
Estrace
Estring
Femring
by Non-Estrogen-Based Drugs
BZA/CE
Osphena
Vaginorm
Market Size Split by Application
Vaginal Gels
Creams
Tablets
Rings
Patches

Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Postmenopausal Vaginal Atrophy Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Postmenopausal Vaginal Atrophy Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Postmenopausal Vaginal Atrophy Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Postmenopausal Vaginal Atrophy Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Postmenopausal Vaginal Atrophy Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Postmenopausal Vaginal Atrophy Drugs are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Postmenopausal Vaginal Atrophy Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Postmenopausal Vaginal Atrophy Drugs Product
1.2 Key Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
1.4.2 Premarin
1.4.3 Vagifem
1.4.4 Estrace
1.4.5 Estring
1.4.6 Femring
1.5 Market by Application
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
1.5.2 Vaginal Gels
1.5.3 Creams
1.5.4 Tablets
1.5.5 Rings
1.5.6 Patches
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size
2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2016-2025
2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2016-2025
2.2 Postmenopausal Vaginal Atrophy Drugs Growth Rate by Regions
2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions
2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers
3.1.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2016-2018)
3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2016-2018)
3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
3.4 Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Category
3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type
4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type
4.3 Postmenopausal Vaginal Atrophy Drugs Price by Type

5 Breakdown Data by Application
5.1 Overview
5.2 Global Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application

6 North America
6.1 North America Postmenopausal Vaginal Atrophy Drugs by Countries
6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Countries
6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Postmenopausal Vaginal Atrophy Drugs by Type
6.3 North America Postmenopausal Vaginal Atrophy Drugs by Application
6.4 North America Postmenopausal Vaginal Atrophy Drugs by Company

7 Europe
7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Countries
7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Countries
7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Postmenopausal Vaginal Atrophy Drugs by Type
7.3 Europe Postmenopausal Vaginal Atrophy Drugs by Application
7.4 Europe Postmenopausal Vaginal Atrophy Drugs by Company

8 Asia Pacific
8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Countries
8.1.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Countries
8.1.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Type
8.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Application
8.4 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Company

9 Central & South America
9.1 Central & South America Postmenopausal Vaginal Atrophy Drugs by Countries
9.1.1 Central & South America Postmenopausal Vaginal Atrophy Drugs Sales by Countries
9.1.2 Central & South America Postmenopausal Vaginal Atrophy Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Postmenopausal Vaginal Atrophy Drugs by Type
9.3 Central & South America Postmenopausal Vaginal Atrophy Drugs by Application
9.4 Central & South America Postmenopausal Vaginal Atrophy Drugs by Company

10 Middle East and Africa
10.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Countries
10.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Countries
10.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Type
10.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Application
10.4 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Company

11 Company Profiles
11.1 Actavis plc
11.1.1 Actavis plc Company Details
11.1.2 Company Description
11.1.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.1.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.1.5 Recent Development
11.2 Bionovo, Inc.
11.2.1 Bionovo, Inc. Company Details
11.2.2 Company Description
11.2.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.2.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.2.5 Recent Development
11.3 Endoceutics, Inc.
11.3.1 Endoceutics, Inc. Company Details
11.3.2 Company Description
11.3.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.3.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.3.5 Recent Development
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Company Details
11.4.2 Company Description
11.4.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.4.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.4.5 Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Details
11.5.2 Company Description
11.5.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.5.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.5.5 Recent Development
11.6 Teva Pharmaceuticals Ltd.
11.6.1 Teva Pharmaceuticals Ltd. Company Details
11.6.2 Company Description
11.6.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.6.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.6.5 Recent Development
11.7 Therapeutics MD, Inc.
11.7.1 Therapeutics MD, Inc. Company Details
11.7.2 Company Description
11.7.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.7.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.7.5 Recent Development
11.8 Shionogi & Company
11.8.1 Shionogi & Company Company Details
11.8.2 Company Description
11.8.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.8.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.8.5 Recent Development
11.9 Allergan plc
11.9.1 Allergan plc Company Details
11.9.2 Company Description
11.9.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.9.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.9.5 Recent Development
11.10 Shionogi & Co. Ltd.
11.10.1 Shionogi & Co. Ltd. Company Details
11.10.2 Company Description
11.10.3 Sales, Revenue and Gross Margin of Postmenopausal Vaginal Atrophy Drugs
11.10.4 Postmenopausal Vaginal Atrophy Drugs Product Description
11.10.5 Recent Development

12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
12.1 Market Opportunities and Drivers
12.2 Market Challenges
12.3 Market Risks/Restraints
12.4 Key World Economic Indicators

13 Value Chain and Sales Channels Analysis
13.1 Value Chain Analysis
13.1.1 Typical Suppliers of Key Postmenopausal Vaginal Atrophy Drugs Raw Material
13.1.2 Postmenopausal Vaginal Atrophy Drugs Customers
13.2 Sales Channels Analysis
13.2.1 Sales Channels Analysis
13.2.2 Distributors

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer

List of Tables and Figures

Figure Picture of Postmenopausal Vaginal Atrophy Drugs
Figure Global Postmenopausal Vaginal Atrophy Drugs Production (K Units) and CAGR (%) Comparison by Types (Product Category) (2013-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Production Market Share by Types (Product Category) in 2017
Figure Premarin Product Picture
Table Major Manufacturers of Premarin
Figure Vagifem Product Picture
Table Major Manufacturers of Vagifem
Figure Estrace Product Picture
Table Major Manufacturers of Estrace
Figure Estring Product Picture
Table Major Manufacturers of Estring
Figure Femring Product Picture
Table Major Manufacturers of Femring
Table Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application 2018-2025 (K Units)
Figure Vaginal Gels
Figure Creams
Figure Tablets
Figure Rings
Figure Patches
Figure Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure Global Postmenopausal Vaginal Atrophy Drugs Market Size 2016-2025 (Million US$)
Figure Global Postmenopausal Vaginal Atrophy Drugs Sales 2016-2025 (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Market Size by Regions 2016-2025 (K Units) & (Million US$)
Table Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions 2016-2025 (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Regions 2016-2025
Figure Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Regions 2016-2025
Figure 2017 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Regions
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions 2016-2025 (Million US$)
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Regions 2016-2025
Figure Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Regions 2016-2025
Figure 2017 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Regions
Table Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2016-2018) (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers (2016-2018)
Figure Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers in 2017
Table Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2016-2018) (Million US$)
Table Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2016-2018)
Figure Postmenopausal Vaginal Atrophy Drugs Value Share by Manufacturers in 2017
Table Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Price (2016-2018) (USD/Unit)
Table Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Category
Table Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016-2025) (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2016-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2017
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2016-2025) (Million US$)
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2016-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2016-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type in 2017
Table Postmenopausal Vaginal Atrophy Drugs Price by Type 2013-2018 (USD/Unit)
Table Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2016-2025) (K Units)
Table Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2016-2025)
Figure Global Sales Postmenopausal Vaginal Atrophy Drugs Market Share by Application (2016-2025)
Figure Global Sales Postmenopausal Vaginal Atrophy Drugs Market Share by Application (2016-2025)
Figure North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2016-2025 (K Units)
Figure North America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table North America Postmenopausal Vaginal Atrophy Drugs Sales by Countries (2016-2025) (K Units)
Table North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries
Table North America Postmenopausal Vaginal Atrophy Drugs Revenue by Countries (2016-2025) (Million US$)
Table North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries
Figure United States Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure United States Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016-2025) (K Units)
Table North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2025)
Figure 2017 North America Postmenopausal Vaginal Atrophy Drugs Market Share by Type
Table North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2016-2025) (K Units)
Table North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2025)
Figure 2017 North America Postmenopausal Vaginal Atrophy Drugs Market Share by Application
Table North America Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2018) (K Units)
Table North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2016-2018)
Figure North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2017
Figure Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2016-2025 (K Units)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table Europe Postmenopausal Vaginal Atrophy Drugs Sales by Countries (2016-2025) (K Units)
Table Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries
Table Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Countries (2016-2025) (Million US$)
Table Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries
Figure Germany Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (K Units)
Figure France Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (K Units)
Figure UK Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure UK Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016-2025) (K Units)
Table Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2025)
Figure 2017 Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Type
Table Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2016-2025) (K Units)
Table Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2025)
Figure 2017 Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Application
Table Europe Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2018) (K Units)
Table Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2016-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2017
Figure Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2016-2025 (K Units)
Figure Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Countries (2016-2025) (K Units)
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Countries (2016-2025) (Million US$)
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries
Figure China Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure India Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure India Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Australia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Indonesia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Indonesia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Malaysia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Malaysia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Philippines Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Philippines Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Thailand Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Thailand Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Vietnam Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Vietnam Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Singapore Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Singapore Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016-2025) (K Units)
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2025)
Figure 2017 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Share by Type
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Application (2016-2025) (K Units)
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2025)
Figure 2017 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Share by Application
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2018) (K Units)
Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2016-2018)
Figure Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2017
Figure Central & South America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2016-2025 (K Units)
Figure Central & South America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Sales by Countries (2016-2025) (K Units)
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 Central & South America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Revenue by Countries (2016-2025) (Million US$)
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 Central & South America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Argentina Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Argentina Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016-2025) (K Units)
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2025)
Figure 2017 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Share by Type
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2016-2025) (K Units)
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2025)
Figure 2017 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Share by Application
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2018) (K Units)
Table Central & South America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2016-2018)
Figure Central & South America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2017
Figure Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2016-2025 (K Units)
Figure Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Countries (2016-2025) (K Units)
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Countries
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Countries (2016-2025) (Million US$)
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Countries
Figure GCC Countries Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure GCC Countries Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2025) (K Units)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016-2025) (K Units)
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2025)
Figure 2017 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share by Type
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2016-2025) (K Units)
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2025)
Figure 2017 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share by Application
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Company (2016-2018) (K Units)
Table Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2016-2018)
Figure Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2017
Table Actavis plc Company Details
Table Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Actavis plc Recent Development
Table Bionovo, Inc. Company Details
Table Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Bionovo, Inc. Recent Development
Table Endoceutics, Inc. Company Details
Table Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Endoceutics, Inc. Recent Development
Table Novo Nordisk A/S Company Details
Table Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Novo Nordisk A/S Recent Development
Table Pfizer Inc. Company Details
Table Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Pfizer Inc. Recent Development
Table Teva Pharmaceuticals Ltd. Company Details
Table Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Teva Pharmaceuticals Ltd. Recent Development
Table Therapeutics MD, Inc. Company Details
Table Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Therapeutics MD, Inc. Recent Development
Table Shionogi & Company Company Details
Table Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Shionogi & Company Recent Development
Table Allergan plc Company Details
Table Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Allergan plc Recent Development
Table Shionogi & Co. Ltd. Company Details
Table Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Shionogi & Co. Ltd. Recent Development
Figure GDP by Regions / Largest Economies Pie Chart in 2016
Figure G20 GDP Long-Term Forecast Total, Million US dollars, 2060
Figure G20 Gross Domestic Product (GDP)Total, US Dollars/Capita, 2016
Figure Saving Rate Total, % of GDP, 2015
Table Postmenopausal Vaginal Atrophy Drugs Value Chain
Table Typical Suppliers of Key Postmenopausal Vaginal Atrophy Drugs Raw Material
Table Postmenopausal Vaginal Atrophy Drugs Customers List
Table Postmenopausal Vaginal Atrophy Drugs Sales Channels
Table Postmenopausal Vaginal Atrophy Drugs Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Choose License Type